Thrombosis News and Research

Latest Thrombosis News and Research

Avesthagen completes development of microalgae based vegetarian DHA omega 3 essential fatty acid

Avesthagen Limited announced completion of a landmark project for the development of AvestaDHA(TM) - a vegetarian source of DHA (docohexanoic acid) omega 3 essential fatty acid based on an innovative approach using naturally occurring microalgae.

17 Feb 2011

FDA grants 510(k) clearance to Venous Health's Vasculaire Compression System in the US

Venous Health Systems, a developer of solutions for treating vascular insufficiency by enhancing blood circulation, today announced that it has received 510 clearance from the Food & Drug Administration to market the Vasculaire Compression System in the United States.

15 Feb 2011

AngioDynamics launches new Morpheus SMART PICC bedside insertion kit and 5 French Dual Lumen PICC

AngioDynamics announced today the launch of a new Morpheus® SMART PICC bedside insertion kit and new 5 French Dual Lumen Peripherally Inserted Central Catheter (PICC) as part of the continued growth of its Morpheus SMART PICC line.

14 Feb 2011

JTH publishes positive TB-402 Phase II trial results for VTE treatment after orthopaedic surgery

ThromboGenics NV and co-development partner BioInvent International announce today that the positive TB-402 Phase II trial results, evaluating the product's efficacy and safety for the prevention of venous thromboembolism afterorthopaedic surgery, have been published in the Journal of Thrombosis and Haemostasis.

14 Feb 2011

Neurologic and neurosurgical patients do not receive therapy to prevent VTE: Study

Patients with strokes, brain tumors and spinal cord injuries are at high risk for life-threatening blood clots, but many do not receive preventive therapy, Loyola University Health System researchers report.

14 Feb 2011

Genetic testing for inherited blood-clotting abnormalities not routinely recommended for VTE patients

Genetic testing for inherited blood-clotting abnormalities is not routinely recommended for patients with venous thromboembolism (VTE) of unknown cause, according to a new expert panel statement in a recent issue of Genetics in Medicine, the official peer-reviewed journal of The American College of Medical Genetics (ACMG).

11 Feb 2011

Study: Drug-eluting stents outperform BMS for revascularization of CTOs

A systematic review of medical evidence has determined drug-eluting stents outperform bare metal stents for revascularization of chronic total occlusions.

10 Feb 2011

PolyMedix commences PMX-60056 Phase 2 clinical trial in patients undergoing PCI

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has initiated a Phase 2 clinical trial, following conclusion of a review by the United States Food and Drug Administration (FDA) of a protocol submitted by PolyMedix, to assess the safety and efficacy of its heptagonist, PMX-60056, in reversing heparin in patients undergoing Percutaneous Coronary Intervention (PCI) procedures.

9 Feb 2011

Pervasis' Vascugel granted Fast Track review status for prevention of hemodialysis access failure in ESRD patients

Pervasis Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track review status for Vascugel® for the prevention of hemodialysis access failure in patients with end stage renal disease (ESRD).

9 Feb 2011

CVT more common than previously thought, disproportionally affects pregnant women

A rare and often underreported form of stroke that involves veins instead of arteries is more common than previously thought, according to the American Heart Association's first scientific statement on diagnosing and managing cerebral venous thrombosis (CVT).

4 Feb 2011

Scientia Advisors: Unmet need for new medical technologies to treat CVI and blood clots

In light of an aging population and increasing chronic vascular disease, there is a tremendous unmet need for new medical technologies to treat potentially dangerous chronic venous insufficiency (CVI) and blood clots, according to a Scientia Advisors review of the vascular device market released today. Both the CVI and the thrombosis segments present significant opportunities for medical device innovators.

3 Feb 2011

Inspiration presents IB1001 PK data for treatment of hemophilia B

Inspiration Biopharmaceuticals, today presented pharmacokinetic data on its lead product, IB1001, a recombinant factor IX for the treatment and prevention of bleeding in individuals with hemophilia B.

3 Feb 2011

Inspiration presents IB1001 PK data at European haemophilia congress

Ipsen today announced that its partner Inspiration Biopharmaceuticals, Inc. (Inspiration) presented pharmacokinetic (PK) data on its lead product, IB1001, a recombinant factor IX (FIX) for the treatment and prevention of bleeding in individuals with hemophilia B.

3 Feb 2011

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

Merck announced today that data from the pivotal Phase III study with GARDASIL in males were published in the February 3 issue of the New England Journal of Medicine.

3 Feb 2011

Isis commences ISIS-FXIRx Phase 1 study for treatment of clotting disorders

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 1 study of ISIS-FXIRx, an antisense drug designed to treat clotting disorders. ISIS-FXIRx inhibits the production of Factor XI, a clotting factor that is an important component of the coagulation pathway. Because of its role in the intrinsic coagulation pathway, inhibition of Factor XI could offer an effective approach for preventing the formation of blood clots with a lower risk of bleeding.

2 Feb 2011

Mother’s stroke history can help predict daughter’s risk of heart attack

If you're a woman and your mother had a stroke, you may have a risk of heart attack in addition to a higher risk of stroke, according to new research on family history and heart disease published in the American Heart Association journal Circulation: Cardiovascular Genetics.

2 Feb 2011

PhRMA: 299 medicines under development for prevention and treatment of heart disease and stroke

An American dies of heart disease every 39 seconds, and African Americans suffer a higher death rate from heart disease and stroke than Americans overall. Partly as a result of having the highest prevalence of high blood pressure in the world, African Americans have a 1.5 times greater rate of heart disease death than other Americans and a 1.8 times greater rate of fatal stroke.

1 Feb 2011

Research sheds new light on venous thromboembolism following liver resections

Patients undergoing liver surgery have long been considered to be at low risk of venous thromboembolism. However, pulmonary embolism has recently emerged as an increasingly frequent and potentially fatal complication following liver resections.

1 Feb 2011

Ligand announces acquisition of CyDex Pharmaceuticals

Ligand Pharmaceuticals Incorporated today announced it has acquired privately held CyDex Pharmaceuticals, for a combination of cash and contingent payments.

26 Jan 2011

Triad alcohol prep pads with ARIXTRA Starter Kits not to be used

GlaxoSmithKline (GSK) has become aware of a United States market recall of all lots of alcohol prep pads, swabs and swabsticks manufactured by the Triad Group and marketed under various brand names. The Triad Group recall has been initiated due to concerns about potential microbial contamination of the alcohol products with Bacillus cereus that could potentially lead to life-threatening infections.

25 Jan 2011

Thrombosis News and Research

Latest Thrombosis News and Research

Avesthagen completes development of microalgae based vegetarian DHA omega 3 essential fatty acid

FDA grants 510(k) clearance to Venous Health's Vasculaire Compression System in the US

AngioDynamics launches new Morpheus SMART PICC bedside insertion kit and 5 French Dual Lumen PICC

JTH publishes positive TB-402 Phase II trial results for VTE treatment after orthopaedic surgery

Neurologic and neurosurgical patients do not receive therapy to prevent VTE: Study

Genetic testing for inherited blood-clotting abnormalities not routinely recommended for VTE patients

Study: Drug-eluting stents outperform BMS for revascularization of CTOs

PolyMedix commences PMX-60056 Phase 2 clinical trial in patients undergoing PCI

Pervasis' Vascugel granted Fast Track review status for prevention of hemodialysis access failure in ESRD patients

CVT more common than previously thought, disproportionally affects pregnant women

Scientia Advisors: Unmet need for new medical technologies to treat CVI and blood clots

Inspiration presents IB1001 PK data for treatment of hemophilia B

Inspiration presents IB1001 PK data at European haemophilia congress

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

Isis commences ISIS-FXIRx Phase 1 study for treatment of clotting disorders

Mother’s stroke history can help predict daughter’s risk of heart attack

PhRMA: 299 medicines under development for prevention and treatment of heart disease and stroke

Research sheds new light on venous thromboembolism following liver resections

Ligand announces acquisition of CyDex Pharmaceuticals

Triad alcohol prep pads with ARIXTRA Starter Kits not to be used

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Thrombosis News and Research

Latest Thrombosis News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in